MedTrace Logo

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

NCT00471419 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2012-06-05

No results posted yet for this study

Summary

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Conditions

  • Dry Eye

Interventions

DRUG

Rimexolone

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Michael Brubaker, PhD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471419 on ClinicalTrials.gov